Author:
Yu Guangjie,Li Yuhuan,Cui Zhihua,Morris Nicholas P.,Weinberg Andrew D.,Fox Bernard A.,Urba Walter J.,Wang Lixin,Hu Hong-Ming
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Coley, W. B. The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med. 3, (Surg Sect), 1–48 (1910).
2. Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371, 2189–99 (2014).
3. Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976–83 (2016).
4. Armand, P. et al. Programmed Death-1 Blockade with Pembrolizumab in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure. J Clin Oncol. 34, 3733–39 (2016).
5. Dimberu, P. M. & Leonhardt, R. M. Cancer Immunotherapy Takes a Multi-Faceted Approach to Kick the Immune System into Gear. Yale J Biol Med. 84, 371–380 (2011).
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献